- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.09. | BioLineRx forges partnership with Norwegian biotech to advance cancer candidate | ||
| 29.09. | After surprise trial listing, Applied Tx still doesn't have any updates on its rare disease asset | ||
| 29.09. | Gilead pumps up virology pipeline with drug transporter deal | ||
| 29.09. | IO lays off 50% of employees after FDA derails cancer vaccine approval plan | ||
| 29.09. | Enanta sees RSV drug fail phase 2b but finds positives in secondaries and subgroup | ||
| 29.09. | MoonLake's stock crashes after high placebo rate eclipses IL-17 drug's phase 3 readouts | ||
| 29.09. | Genmab pays $8B to buy Merus and its phase 3 bispecific that wowed analysts | ||
| 26.09. | Biogen officially ends all AAV gene therapy work, prompting team restructure | ||
| 26.09. | New nine-figure ARPA-H programs seek to deliver custom gene editing treatments to more patients | ||
| 26.09. | Eli Lilly opens incubator site in San Diego, with 'several' biotechs already on board | ||
| 26.09. | Fierce Biotech's Fierce 15 | ||
| 26.09. | US biotechs think twice about EU licensing deals amid Trump's drug pricing campaign | ||
| 25.09. | NIH earmarks $87M for new organoid center as pivot away from animal testing continues | ||
| 25.09. | Eli Lilly withdraws phase 2b trial of $1.9B obesity bet before starting enrollment | ||
| 25.09. | Heidelberg to lay off 75% of staff after milestone becomes millstone | ||
| 24.09. | Average biopharma biobucks decline, while upfront deal payments rise: SRS Acquiom | ||
| 24.09. | Sparrow flies forward with $95M series B for midstage diabetes asset | ||
| 24.09. | Harmony's pivotal Fragile X trial flops as high placebo response creates discord | ||
| 24.09. | uniQure hopes to launch 1st Huntington's gene therapy next year following phase 1/2 success | ||
| 24.09. | Cyclerion cycles through latest pivot, reinventing itself as neuro biotech | ||
| 23.09. | Big Pharma-backed Rome Therapeutics nears end of road with planned layoffs and strategic review | ||
| 23.09. | Wall Street spotlight: NYSE honors this year's Fierce 15 winners | ||
| 23.09. | Seres shrinks head count by 25% to fund phase 2 study of infection biotherapeutic | ||
| 23.09. | Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma | ||
| 23.09. | Roche's 'top three' obesity ambition not reliant on developing one megablockbuster |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .